Navigation Links
Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film
Date:12/2/2008

ng-term value.

The Company's commercialization strategy for all PharmFilm(R) products is to partner with the innovator or other specialty pharma or leading consumer products companies who have the core competency to sell-in and manage the sales and marketing of the products. For the Company's existing and future partners, PharmFilm(R) formulations represent revenue-life cycle extensions for products with patent lives that have expired or are approaching expiration. PharmFilm(R) is also a tool to help sales and marketing partners differentiate in competitive markets while offering unique advantages over drugs dosed by traditional tablets, capsules and ODTs.

SafeHarbor Statement

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein. Risk factors that might affect such forward-looking statements include those set forth in Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2007, in Item 1A of the Company's subsequent Quarterly Reports on Form 10-Q, in other of the Company's filings with the SEC from time to time, including Current Reports on Form 8-K, and on general industry and economic conditions. Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine
2. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
3. Introducing Strativa Pharmaceuticals
4. Cerimon Pharmaceuticals Appoints James S. Shannon, M.D., to Board of Directors
5. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
6. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
7. Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug
8. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
9. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
10. Celator(R) Pharmaceuticals to Present at Piper Jaffray Health Care Conference and Mid-Atlantic Capital Conference
11. Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... March 27, 2015 Working in collaboration ... in London , Richmond Pharmacology is the ... Phase 3 study for an investigational RNAi therapeutic being developed ... affecting the nerves and heart. Read press ... Based at St Georges University of ...
(Date:3/27/2015)... ROCKVILLE, Md. , March 27, 2015  CASI ... dedicated to the acquisition, development and commercialization of innovative ... the global market with a commercial focus on ... the three and 12 months ended December 31, 2014.  ... of ($1.6 million), or ($0.05) per share, for the ...
(Date:3/26/2015)... 2015  Roka Bioscience, Inc. (NASDAQ: ROKA ... advanced testing solutions for the detection of foodborne ... three months and full year ended December 31, ... for the quarter ended December 31, 2014 was ... quarter of 2013 and $1.5 million for the ...
(Date:3/26/2015)... TORONTO , March 26, 2015 /PRNewswire/ - SQI ... SQIDF) announced that after dealing with certain matters, including ... of shareholders held on March 26, 2015 (the "Meeting") ... until April 8, 2015 at 11:00 a.m. ( ... Meeting has been changed from that previous disclosed. The ...
Breaking Biology Technology:CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7SQI Diagnostics Inc. Announces Adjournment of Meeting 2
... Netherlands , April 28, 2010 , Pepscan, the Netherlands ... of immune therapeutics, today,announced that it reached a partnering agreement for ... of the,agreement Pepscan will receive an undisclosed cash payment as well ... , , ...
... , S-HERTOGENBOSCH, The Netherlands , April ... novel methods in,immunotherapy with the most recent insights in oncology to develop ... , , ... Netherlands , April 27, 2010 - Immunovo BV, a new,biotechnology ...
... The Johns Hopkins University School of Medicine and The ... to advance the development and use of stem cells in therapies for a ... to use stem cells and foster joint research projects. , ... The collaborative program will encompass training for Johns ...
Cached Biology Technology:Pepscan Signs Partnering Agreement With Immunovo for its Therapeutic Vaccine Portfolio 2Pepscan Signs Partnering Agreement With Immunovo for its Therapeutic Vaccine Portfolio 3Immunovo BV- A New Biotechnology Company is Announced 2The New York Stem Cell Foundation and The Johns Hopkins University School of Medicine to Collaborate on Stem Cell Research 2The New York Stem Cell Foundation and The Johns Hopkins University School of Medicine to Collaborate on Stem Cell Research 3The New York Stem Cell Foundation and The Johns Hopkins University School of Medicine to Collaborate on Stem Cell Research 4The New York Stem Cell Foundation and The Johns Hopkins University School of Medicine to Collaborate on Stem Cell Research 5
(Date:3/3/2015)... March 3, 2015 Cryoport, Inc. ... advanced cryogenic logistics solutions for the life ... cells, cell lines, clinical research organizations, vaccine ... announced the expansion of its relationship with ... ("Fred Hutch") Clinical Research Division with the ...
(Date:3/2/2015)... HUNTSVILLE, Ala. , March 2, 2015 /PRNewswire/ ... transaction processing. Data protection company Tharon Rankins Enterprises ... product that provides an ultra-safe way for businesses ... as their financial transactions. Beconux ... by Tharon Rankins Enterprises. Functioning similarly to an ...
(Date:2/25/2015)... Feb. 25, 2015  ABC Financial Services (ABC), ... the Health and Fitness Industry, today announced enhancements ... MYiCLUBonline.  The latest upgrade includes advances to the ... cardless check-in via Identity One fingerprint biometrics. The ... through interactive displays at the International Health, Racquet ...
Breaking Biology News(10 mins):Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Personal Data Protection Company Launches New Product 2ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3
... jobs, clean energy and a more sustainable use of ... talks. During the summit, the role of Earth observation ... blueprint to rethink economic growth, advance social equity and ... in Rio de Janeiro, Brazil. ,Now, 20 years later, ...
... previously documented that substances from the South African plant ... daffodils have an effect on the mechanisms in ... has now yielded further results, since a team based ... recently shown how several South African daffodils contain plant ...
... Innes Centre is the author of a new book ... define life. http://youtu.be/urDhZkCtkvM What ... develops into an infant, a child who learns to ... For many years, scientists have generally thought these great ...
Cached Biology News:Earth observation for us and our planet 2South African daffodils may be a future cure for depression 2'Cells to Civilizations: The Principles of Change That Shape Life' 2
... PP2A1, purified Formulation: 50mM Tris-HCl, ... Brij-35, 0.2mM PMSF, 1mM benzamidine, ... Properites: PP2A1 (Protein Phosphatase 2A1) ... ammonium sulfate precipitation, QSepharose,amino-hexyl agarose, ...
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
...
... Immunogen : Recombinant human HMGN2/HMG-17 ... BSA, 0.15M NaCl, 0.05% sodium ... glycerol to 30% Quality Assurance: ... acid extracts of murine 10T ...
Biology Products: